<DOC>
	<DOC>NCT02626780</DOC>
	<brief_summary>The general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived SVF for the treatment of alopecia.</brief_summary>
	<brief_title>Adipose-derived SVF for Treatment of Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>1. Males and females 18 60 years of age and older that have been diagnosed with androgenetic alopecia. 2. Subjects will be in good health (ASA Class III) with a BMI &lt; 35. Must have at least a 2cm x 2cm spot on the scalp which shows evidence of alopecia without scarring or traumatic injury 3. Able and willing to make the required study visits. 4. Able and willing to give consent and follow study instructions. 5. Must speak, read and understand English 1. History of bleeding disorders, anticoagulation therapy that cannot be stopped 14 days prior to injection 2. Allergic to lidocaine, epinephrine, valium or sodium phosphate 3. Individuals with a propensity for keloids 4. Individuals with diminished decisionmaking capacity will not be included in this research study 5. Current use of antiinflammatory or anticoagulation medications that affect bleeding or are for bleeding disorders. These include: Plavix, Warfarin (Coumadin, Jantoven, Marfarin). In addition, if any of the following medicines are used two (2) weeks prior to surgery the patient will be ineligible. 6. Use of concomitant treatments, including topical medications, oral medications, mesotherapy, nonablative fractional laser treatment, lowlevel laser therapy, interfollicular PRP injection and hair transplantation within the preceding 6 months. 7. All smokers and other tobacco users.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>